On July 19, 2018 Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, reported that the company has submitted a clinical trial authorization (CTA) application to the relevant regulatory authorities to start a phase I study of its wholly-owned bispecific drug candidate ATOR-1015 (Press release, Alligator Bioscience, JUL 19, 2018, View Source [SID1234527787]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The upcoming phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with advanced solid cancer. The study will be conducted at five sites in Sweden and Denmark and will enroll up to 50 patients. The primary aim of the study is to investigate the safety and tolerability of ATOR-1015 and establish the recommended dose for the subsequent phase II studies. ATOR-1015 is intended to be the first CTLA-4 and OX40-binding bispecific antibody to achieve a strong anti-tumor effect, either as a monotherapy or in combination with currently established immunotherapies such as PD-1 and PD-L1 blockers. It is expected to be suitable for treating a large number of different forms of cancer.

"We are very pleased to announce the CTA submission and look forward to starting patient recruitment as fast as possible after regulatory approval. Based on a strong preclinical data package demonstrating that ATOR-1015 localizes to the tumor and selectively activates the immune system in the tumor area, we have high expectations of this first-in-class drug candidate," said Per Norlén CEO of Alligator Bioscience.

As previously communicated, Alligator has appointed Theradex Oncology, a global contract research organization with extensive expertise in oncology clinical development, to conduct the phase I study.

For further information, please contact:

Cecilia Hofvander, Director Investor Relations & Communications

Phone +46 46 286 44 95

E-mail: [email protected]

This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 4:10 p.m. CEST on July 19, 2018.

About ATOR-1015

ATOR-1015 is a next generation CTLA-4 bispecific antibody developed for tumor-directed immunotherapy with increased capability of regulatory T-cell depletion. It is wholly-owned by Alligator. ATOR-1015 binds to two different immune receptors: the checkpoint receptor CTLA-4 and the co-stimulatory receptor OX40. The immune activation is increased in areas where both target molecules are expressed at high levels, notably in the tumor microenvironment, which is believed to reduce adverse immune reactions.

On July 19, 2018 Acorda Therapeutics, Inc. (Nasdaq:ACOR) reported that it will host a conference call and webcast to report its second quarter 2018 update and financial results on Thursday, August 2 at 8:30 a.m. ET (Press release, Acorda Therapeutics, JUL 19, 2018, View Source [SID1234527776]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (international) and reference the access code 4898766. The presentation will be available on the Investors section of www.acorda.com.

A replay of the call will be available from 11:30 a.m. ET on August 2, 2018 until 11:59 p.m. ET on September 1, 2018. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international); reference code 4898766. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com.

On July 19, 2018 Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, reported the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia (Press release, Yisheng US Biopharma, JUL 19, 2018, View Source [SID1234528627]). The two divisions represent the first expansion of Yisheng Biopharma business and product sales operations into an ASEAN member country.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The opening of these two divisions is an important milestone in company history," commented Zhang Yi, Founder and Chairman of Yisheng Biopharma. "Our product YivykaTM is approved in Cambodia for the treatment of advanced solid tumors, including lung, breast, liver, colorectal and stomach cancers. We are pleased to be in a position to expand access to the benefits that this product will bring to cancer patients and are grateful for the support we have received from the Ministry of Health of the Kingdom of Cambodia."

"ASEAN countries have witnessed a significant economic boom over the last decade and represent one of the fastest growing markets for the biopharmaceutical industry," added David Shao, Ph.D., President and CEO of Yisheng Biopharma. "With a population of over 600 million under-served individuals in these countries, we are committed to expanding and deepening our presence in this region of southeast Asia. We are conducting drug development in this region, with programs in immuno-oncology, rabies and hepatitis B infection, and are well positioned to introduce a series of innovative products into this region."

YivykaTM is an innovative immuno-oncology drug recently granted a drug registration license by the Ministry of Health of the Kingdom of Cambodia. YivykaTM is the first biological product introduced into the Cambodia market by Yisheng Biopharma.

About Yisheng Biopharma Co., Ltd.

Yisheng Biopharma is a global biopharmaceutical company discovering, developing and commercializing innovative immunological biologics. With approximately 700 employees worldwide and operations in China, the United States, Singapore and certain Southeast Asian countries.

On July 19, 2018 GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) reported a Material Transfer Agreement (MTA) between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota (Press release, GT Biopharma , JUL 19, 2018, View Source [SID1234539527]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, this Major Pharmaceutical Company will supply a formulation of their multibillion dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

Dr. Vallera is the lead researcher for GT Biopharma’s bispecific antibody drug conjugate (ADC) program, and the innovator of oncology drug candidate DT2219, also known as OXS-1550. OXS-1550 targets two antigens on cancer cells and contains a cytotoxic payload thereby increasing the probability it will kill the cancer cells. OXS-1550 targets cancer cells expressing the CD19 receptor and/or CD22 receptors which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploy its cytotoxic diphtheria toxin payload which inhibits protein synthesis and kills the cancer cells.

Initial pre-clinical work performed by Dr. Vallera suggests a much greater effect when OXS-1550 is given in combination with this established oncology drug. Dr. Vallera said: "I am looking forward to conducting these experiments. Early work suggests that these two agents would be a great combination in the treatment of certain cancers. This initial work will assist us in deciding what tumors to target and the doses to employ."

GT Biopharma’s Chairman and Chief Executive Officer (CEO) Dr. Raymond Urbanski said: "This is a tremendous step forward for the OXS-1550 program. Pre-clinical data suggests that the combination of OXS-1550 and this agent is highly potent against certain tumor cell lines. This MTA will allow further studies in animal models to both confirm the effects as well as ascertain which tumor types are the most susceptible to this potent combination."

On July 19, 2018 Replimune Group, Inc., a biotechnology company developing oncolytic immunotherapies derived from its Immulytic platform, reported the pricing of its initial public offering of 6,700,000 shares of common stock at a public offering price of $15.00 per share for gross proceeds of $100.5 million, before underwriting discounts and commissions and other offering expenses payable by Replimune (Press release, Replimune, JUL 19, 2018, View Source [SID1234530184]). In addition, Replimune has granted the underwriters a 30-day option to purchase up to 1,005,000 additional shares of its common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Replimune. Replimune’s common stock has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading under the ticker symbol "REPL" on July 20, 2018. The offering is expected to close on July 24, 2018, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan, Leerink Partners and BMO Capital Markets are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on July 19, 2018. The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering will be filed with the SEC and may be obtained, when available, by visiting EDGAR on the SEC website at www.sec.gov or from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by e-mail at [email protected]; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by e-mail at [email protected]; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at (800) 414-3627, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.